Peterson v Merck Sharpe & Dohme (Aust) Pty Ltd

Link copied
Case Copied 68 min read

FEDERAL COURT OF AUSTRALIA

Peterson v Merck Sharpe & Dohme (Aust) Pty Ltd [2010] FCA 180

Citation: Peterson v Merck Sharpe & Dohme (Aust) Pty Ltd [2010] FCA 180
Parties: GRAEME ROBERT PETERSON v MERCK SHARPE & DOHME (AUSTRALIA) PTY LTD (ACN 000 173 508) and MERCK & CO, INC.
File number: VID 451 of 2006
Judge: JESSUP J
Date of judgment: 5 March 2010
Catchwords:

TORTS – Negligence – Product Liability – Prescription medicine for relief of inflammation – Side-effects – Whether medicine caused or contributed to cardiovascular disease – Whether manufacturers knew or ought to have known of that tendency – Whether they owed duty of care to consumers – Content of duty of care – Whether affected by status of product as prescription medicine – State of scientific uncertainty as to side-effects of medicine – Whether manufacturers undertook sufficient research into side‑effects – Whether medicine should have been withdrawn from market pending resolution of scientific issues – Whether manufacturers breached duty of care by not doing so.

TORTS – Negligence – Product Liability – Prescription medicine for relief of inflammation – Side-effects – Clinical trial presenting signal of cardiovascular risk – Whether discharge of duty of care required medicine to be withdrawn from market – Whether doctors, pharmacists, health care professionals and the public should have been warned – Whether they were warned – Terms of warning that would have been sufficient – Whether sufficiently communicated to doctors – Whether amendment to “Product Information” was sufficient – Manufacturer’s sales representatives claiming medicine safe – Whether justified claim – Whether duty of care breached by failing to warn and/or making safety claim.

TORTS – Negligence – Product Liability – Causation – Prescription medicine for relief of inflammation contributing to applicant’s heart attack – Manufacturer negligently failed to warn of risk and represented safety of medicine – Whether applicant would have declined to take medicine if appropriately warned or if no safety claim made – Whether applicant’s doctor would have chosen not to prescribe medicine.

TRADE PRACTICES – Misleading or deceptive conduct – Prescription medicine for relief of inflammation associated with doubling of risk of heart attack – No warning provided to doctors – “Product Information” for medicine not referring to increased risk – Whether misleading or deceptive conduct on part of corporation marketing the medicine – Sales representatives of corporation claiming medicine safe – Whether misleading or deceptive – Medicine contributed to applicant’s heart attack – Whether applicant’s doctor relied on conduct of corporation – Whether he would have prescribed medicine in any event.

TRADE PRACTICES – Defective goods – Prescription medicine for relief of inflammation associated with doubling of risk of heart attack – No warning provided to doctors – Whether safety of medicine not as such persons generally entitled to expect – Whether defect arose only because of compliance with mandatory standard – Whether state of scientific knowledge not such as to enable defect to be discovered.

TRADE PRACTICES – Unsuitable goods – Prescription medicine for…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Peterson v Merck Sharpe & Dohme (Aust) Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2010] FCA 180
Decision Date

CaseChat Overview and Summary

Peterson sued Merck Sharpe & Dohme (Aust) Pty Ltd, alleging that the defendant's prescription medicine, intended for inflammation relief, caused his cardiovascular disease. The dispute involved whether the manufacturers knew or should have known about the medicine's tendency to cause such side effects, whether they owed a duty of care to consumers, and if they breached this duty by not withdrawing the product from the market or providing adequate warnings. The court had to decide whether the state of scientific uncertainty regarding the side effects absolved the manufacturers of responsibility and whether the manufacturers' actions constituted misleading or deceptive conduct under trade practices law.

The legal issues included whether the manufacturers' duty of care required the withdrawal of the medicine from the market, the adequacy of warnings provided to healthcare professionals and the public, and the effectiveness of the "Product Information" amendment. Additionally, the court needed to determine whether the manufacturers' sales representatives' claims about the medicine's safety were justified, and whether these claims, coupled with the failure to warn, constituted a breach of duty. The court also examined whether the corporation's conduct misled Peterson's doctor, potentially influencing his decision to prescribe the medicine.

The court found that Merck Sharpe & Dohme breached their duty of care by not withdrawing the medicine from the market or adequately warning healthcare professionals and the public about the cardiovascular risks. The court concluded that the manufacturers should have acted upon the clinical trial's signal of cardiovascular risk and provided sufficient warnings. Despite the state of scientific uncertainty, the court held that the manufacturers should have undertaken further research and taken precautionary measures. The court also found that the manufacturers' claims of the medicine's safety were misleading, as they were not supported by the available evidence.

The final orders required the parties to exchange and file with the court their proposed orders reflecting the court’s determination of the claims and any other orders, including those regarding costs, with written notice to be provided to the other parties at least seven days before the listing date for making such orders. The proceeding was to be listed for the making of orders on a date to be fixed, not before 6 April 2010.

Orders

Orders of the court

1. The proceeding be listed for the making of orders on a date to be fixed, not before 6 April 2010.

2. Not less than 7 days before the date so fixed:

(a) the applicant file and serve a minute of the orders proposed by him to reflect the court’s determination of his personal claim;

(b) the second respondent file and serve a minute of the orders proposed by it to reflect the court’s determination of the applicant’s claim in negligence against it;

(c) the parties exchange, and file with the court, minutes of their respective proposals as to the orders which should be made pursuant to the schedule to the order made under s 33ZF of the Federal Court of Australia Act 1976 (Cth) on 30 March 2009; and

(d) any party who or which seeks the making of any other order at this stage of the proceeding, including any order as to costs, provide written notice thereof to the other parties.

Note:

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.